Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding RonapreveTM(a)(b), revenues increased 10%Fourth quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 15% to $3.70 billion versus fourth quarter 2023; full year 2024 Dupixent global net sales increased 22% to $14.15 billion versus 2023Fourth quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 2% versus fourth quarter 2 ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=126299&from ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=126275&from=4 CLASS ...

Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025.The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $3.78 billion, while the same for earnings is pinned at $11.60 per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Dupixent Fuels Growth for REGNA significant chunk of Regeneron’s revenues comes from the sale of its lead drug, Eylea, which is approved for various ophthalmology indi ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of $3.78 billion, representing an increase of 10.1% year over year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timefr ...

Core Viewpoint - The Regeneron Pharmaceuticals, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims related to misleading statements and undisclosed financial practices concerning its product Eylea [1][3][4]. Company Overview - Regeneron is a biotechnology company focused on developing treatments for various diseases, including eye diseases, allergic and inflammatory diseases, cancer, and cardiovascular and metabolic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Regeneron made false statements and failed to disclose that it paid credit card fees to distributors to prevent them from charging customers more for using credit cards to purchase Eylea [3]. - It is alleged that these payments effectively subsidized the prices customers paid, leading to a lower selling price for Eylea and providing Regeneron with a competitive advantage [3]. - The lawsuit also states that Regeneron misrepresented its sales figures and overstated the Average Sales Price (ASP) reported to federal agencies, violating the False Claims Act [3]. Impact of DOJ Complaint - On April 10, 2024, the U.S. Department of Justice filed a complaint against Regeneron under the False Claims Act, alleging that the company failed to report significant discounts provided to drug distributors, which inflated Eylea's ASP and improperly increased Medicare reimbursement [4]. Financial Performance - On October 31, 2024, Regeneron reported third quarter 2024 financial results, revealing only a 3% increase in U.S. net sales for Eylea compared to the third quarter of 2023, with Eylea HD sales at $392 million, missing consensus estimates of $415 million to $425 million [5]. - The report indicated that net product sales of Eylea were adversely impacted by a lower net selling price compared to the previous year, leading to a more than 9% drop in Regeneron's stock price following the announcement [5].

Core Viewpoint - A class action securities lawsuit has been filed against Regeneron Pharmaceuticals, alleging securities fraud that affected investors between November 2, 2023, and October 30, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Regeneron made false statements and concealed payments made to distributors to cover credit card fees, which misled investors about the true sales figures of Eylea [2]. - It is alleged that these payments allowed Regeneron to offer price concessions that lowered Eylea's selling price, thus misleadingly boosting reported sales figures [2]. - The complaint also states that Regeneron failed to report these payments as price concessions, resulting in an overstatement of the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [2]. Group 2: Investor Information - Investors who suffered losses during the specified time frame have until March 10, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, indicating its expertise in handling complex cases [4].

Core Viewpoint - Regeneron Pharmaceuticals, Inc. is facing a securities fraud class action following a significant drop in its stock price, which resulted in a loss of approximately $9 billion in market value due to alleged misleading statements regarding its EYLEA® product [1][5]. Group 1: Legal Issues and Investigations - Hagens Berman has initiated an investigation into Regeneron for potentially misleading investors about its marketing and reimbursement practices related to EYLEA®, urging affected investors to report their losses [2][6]. - The class action lawsuit focuses on Regeneron's compliance with regulations concerning Medicare reimbursement claims, particularly regarding EYLEA® [3]. - The complaint alleges that Regeneron made false statements and failed to disclose various practices that misrepresented the pricing and sales of EYLEA®, including undisclosed credit card fees that effectively lowered the selling price [4]. Group 2: Financial Impact - On October 31, 2024, Regeneron reported disappointing Q3 2024 financial results, with U.S. net sales for EYLEA® and EYLEA HD® increasing only 3% year-over-year, attributed to lower net selling prices and pricing pressure in the anti-VEGF category [5]. - The announcement of these financial results led to a more than 9% decline in Regeneron's share price on the same day [5].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Regeneron Pharmaceuticals, alleging that the company made materially false and misleading statements regarding its pricing practices for Eylea, which may have artificially inflated its reported sales figures [1]. Group 1: Allegations Against Regeneron - The lawsuit claims that Regeneron paid credit card fees to distributors to prevent them from charging Eylea customers more for credit card usage [1]. - These payments allegedly subsidized the prices customers paid when using credit cards, leading to a price concession that lowered Eylea's selling price [1]. - The complaint states that Regeneron's price concessions provided a competitive advantage due to retina practices being sensitive to higher prices for anti-VEGF medications [1]. - As a result of these actions, Regeneron is accused of misleadingly boosting reported Eylea sales and overstating the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 2, 2023, to October 30, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is March 10, 2025, and there is no cost or obligation to participate in the case [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Regeneron Pharmaceuticals due to allegations of misleading statements and violations of federal securities laws related to the pricing and sales of its Eylea drug [2][4][5]. Group 1: Allegations Against Regeneron - The complaint alleges that Regeneron made false and misleading statements regarding credit card fee payments to distributors, which were not disclosed as price concessions [4]. - It is claimed that these undisclosed payments led to inflated reported sales of Eylea and overstated average selling prices (ASP) reported to federal agencies, violating the False Claims Act [4][5]. - The U.S. Department of Justice filed a complaint against Regeneron, stating that the company failed to report millions in discounts, which resulted in inflated Medicare reimbursements [5]. Group 2: Financial Impact and Stock Performance - Following the DOJ announcement, Regeneron's stock price fell by $31.50, or 3.36%, closing at $904.70 on April 12, 2024, with unusually heavy trading volume [6]. - On October 31, 2024, Regeneron reported third-quarter 2024 financial results, revealing only a 3% increase in U.S. net sales for Eylea compared to the previous year, with sales of Eylea HD at $392 million, missing consensus estimates [7]. - The stock price dropped by $84.59, or 9.2%, to close at $838.20 per share on the same day, indicating a significant market reaction to the disappointing sales figures [7].